title: Altered prostanoid signaling contributes to increased skin tumorigenesis in Tpl2 knockout mice.
abstract: Squamous cell carcinoma is the second most common form of skin cancer with the incidence expected to double over the next 20 years. Inflammation is believed to be a critical component in skin cancer progression. Therefore, understanding genes involved in the regulation of inflammatory pathways is vital to the design of targeted therapies. Numerous studies show cyclooxygenases (COXs) play an essential role in inflammation-associated cancers. Tpl2 (MAP3K8) is a protein kinase in the MAP Kinase signal transduction cascade. Previous research using a two-stage skin carcinogenesis model revealed that Tpl2(-/-) mice have significantly higher tumor incidence and inflammatory response than wild-type (WT) controls. The current study investigates whether cyclooxygenase-2 (COX-2) and COX-2- regulated prostaglandins and prostaglandin receptors drive the highly tumorigenic state of Tpl2(-/-) mice by investigating the relationship between Tpl2 and COX-2. Keratinocytes from newborn WT or Tpl2(-/-) mice were treated with 12-O-tetradecanoylphorbol-13-acetate (TPA) for various times over 24 hours. Western analysis revealed significant differences in COX-2 and COX-2 dependent prostanoids and prostanoid receptors. Additionally, in vivo experiments confirmed that COX-2 and COX-2 downstream factors were elevated in TPA-treated Tpl2(-/-) skin, as well as in papillomas from Tpl2(-/-) mice. Use of the selective COX-2 inhibitor Celecoxib showed the increased tumorigenesis in the Tpl2(-/-) mice to primarily be mediated through COX-2. These experiments illustrate COX-2 induction in the absence of Tpl2 may be responsible for the increased tumorigenesis found in Tpl2(-/-) mice. Defining the relationship between Tpl2 and COX-2 may lead to new ways to downregulate COX-2 through the modulation of Tpl2.
authors: Department of Biology, American University, Washington, DC, United States of America.
authors: Kathleen L
authors: KL
authors: DeCicco-Skinner
authors: Sabrina J
authors: SJ
authors: Nolan
authors: Monika M
authors: MM
authors: Deshpande
authors: Erika L
authors: EL
authors: Trovato
authors: Taylor A
authors: TA
authors: Dempsey
authors: Jonathan S
authors: JS
authors: Wiest
mesh_terms: D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000235:genetics* / Q000276:immunology* / Q000473:pathology; D002478:Cells, Cultured; D051546:Cyclooxygenase 2 / Q000276:immunology*; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D005260:Female; D017353:Gene Deletion; D015972:Gene Expression Regulation, Neoplastic; D015603:Keratinocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D020930:MAP Kinase Kinase Kinases / Q000235:genetics*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011453:Prostaglandins / Q000276:immunology*; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D011982:Receptors, Prostaglandin / Q000276:immunology; D015398:Signal Transduction / Q000187:drug effects; D012867:Skin / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism / Q000473:pathology*; D013755:Tetradecanoylphorbol Acetate / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D011453:Prostaglandins; D011518:Proto-Oncogene Proteins; D011982:Receptors, Prostaglandin; C020922:4-O-methyl-12-O-tetradecanoylphorbol 13-acetate; D051546:Cyclooxygenase 2; D020930:MAP Kinase Kinase Kinases; C489843:Map3k8 protein, mouse; D013755:Tetradecanoylphorbol Acetate